About Galen Growth

We fast track your digital health strategy

Galen Growth is the leading HealthTech intelligence, analytics and advisory firm, empowering Fortune 500 companies and leading investors to fast track their growth strategies.

Our Mission

Founded in late 2015 by HealthTech innovators, Galen Growth, operates at the epicenter of HealthTech innovation, aka digital health. Our mission is to solve healthcare system pain points and create significant financial and social value.

To achieve this, we position ourselves as the go to innovation partner of direct collaboration between enterprises, startups and investors to prototype, evaluate and implement HealthTech solutions.

We offer our clients a portfolio of proprietary solutions designed specifically to empower their teams to build, execute and scale their digital health innovation strategies.

We partner with enterprises, investors and startups to fast track and deepen their engagement within this exciting ecosystem.

The Galen Growth Difference

We enable our clients to:

Develop real time actionable insights and transparency to the fast-changing ecosystem

Confidently construct bespoke partnerships for near term business impact

Fast track our clients’ timelines to achieve earlier business impact

Operate with data that is never out of date

Retain ownership of their HealthTech strategy from design to implementation

Build stronger capabilities and sustainable organizational knowledge

Mitigate risks and avoid hype

Our Leadership Team

CEO & Co-founder

Julien de Salaberry

Julien is the CEO and co-founder of Galen Growth Asia (GGA), the leading exclusive HealthTech research, analytics and advisory firm in Asia Pac serving Fortune 500 companies and global investors. GGA has built a portfolio of solutions to catalyse direct collaboration between enterprises, startups and investors to prototype, evaluate and implement HealthTech solutions and create significant financial and social value. GGA was founded by HealthTech innovators and is at the epicentre of digital health innovation in Asia Pacific. We seek to transform healthcare in Asia Pacific through the passion of the innovator, the agility of the startup, the expertise of the enterprise and the funding of the investor. Together, we strive to bring the value and the promise of digital health innovation, in collaboration with all those who believe in improving and democratising patient outcomes across Asia Pacific. Julien is a healthcare change catalyst and evangelist who challenges the status quo in healthcare whilst understanding the world in which healthcare providers and organisations function. He strongly believes that medicine and healthcare are being transformed, similarly to other sectors, by the fourth industrial revolution (IR4). With over 15 years of experience in healthcare with leading brands including Eli Lilly, Boston Scientific, Baxter, GSK, Merck&Co, Julien has a deep understanding of organic and inorganic growth in healthcare in both developed and emerging markets. He has gained extensive international business experience across Europe, Middle East and Asia. In 2012, he founded The Propell Group, a boutique venture investor and advisory firm, based in Singapore, which focuses on HealthTech startups and growth companies. Julien also co-founded the Global Cancer Research & Commercialisation Fund in 2016 to establish greater collaboration and open innovation between research institutes, research foundations and investors from all corners of the globe. Julien co-wrote iDisrupted , (published in November 2014) which focused on creating an understanding of the IR4’s significant technological changes which are just beginning to re-shape our daily lives. He is currently co-writing the sequel to address how it is changing society. In addition, he is a regular speaker on HealthTech / Digital Health Innovation and Disruption. More about Julien de Salaberry
COO

Helene Champoux

Helene is the COO of Galen Growth the leading exclusive HealthTech research, analytics and advisory firm in Asia Pac serving Fortune 500 companies and global investors and is a founding team member. Over the past three years, she has built the commercial operations of the company and has been a key player in developing Galen Growth as the go-to-reference for Asia HealthTech (aka digital health) data, trends and insights for corporates, investors and startups.

Supporting the building of HealthTech Alpha, the most comprehensive HealthTech database and analytics platform being the powerhouse of Galen Growth thought leadership and reports, Helene also leads the ecosystem awareness activities from the media relationships and briefings to engaging with all related events in the industry.

From the creation of the HealthTech Summit, a unique unconference where 50 of the most promising HealthTech startups CEOs across Asia join forces with corporates and investors to work together on building partnerships, Helene is continuously showcasing digital health innovation in Asia. She is also actively involved in facilitating organisational innovation workshops and helping partners’ events as well as taking an active role in numerous women in HealthTech initiatives including speaking at various events to encourage more women in the industry.

Working with industry leaders and innovators on the acceleration of the digital transformation of their organisations, Helene has been working on business model transformation in Asia for many of the largest global brands.

Prior to joining Galen Growth, Helene was responsible for the commercialisation of the energy heritage pool for the Province of Quebec with North American counterparts, for their portfolio of only clean energy, as well as structuring the long term energy deals. Before moving to Singapore, she spent a few years in China working on the international desk of a local trading commodity firm for their metal and aluminum side.

Helene holds a Business degree in Finance and a Master in Communication.

CRO

Dario Heymann

Dario is the Chief Research Offer of Galen Growth. He joined in 2016 as the founding Research Manager where he supported the building of HealthTech Alpha; Asia’s only database and analytics platform dedicated to HealthTech ventures. HealthTech Alpha, remains the only database and analytics provider for digital health in Asia, delivering accurate and regularly curated information to investors, industry innovation leaders, startups CxOs, and researchers.

Since 2018 he is acting as Chief Research Offer, managing the database and the research engagement with clients, such as Pharmaco, insurance companies, investors and tech companies.

As well as overseeing and managing the development of the analytic platform, Dario is also responsible for the overall research and market intelligence of the HealthTech ecosystem in Asia which helps inform and improve organisations’ overall strategy by grounding decisions in real-world evidence and analysis. Dario helps organisations grow by providing insights and comprehensive sources, vital to monitor the pulse of the ecosystem and accelerate business strategies.

Prior to Galen Growth, Dario has worked in drug discovery mainly for the development of novel drugs in oncology, both in pharma and academia in Singapore, China and Germany. Apart from building Galen Growth, Dario is pursuing his doctorate in Material Science and Engineering working on novel biodegradable materials that can be used for prosthesis.

Dario holds Masters in Material Science & Engineering, Biochemistry, and Molecular Biology.

Our Board

Co-founder / Board Director / Co-Founder & CEO of My-Doc

Dr Snehal Patel

Dr Patel co-founded MyDoc and is also a Managing Director of Saena Partners, a Singapore-based investment company. Previously, he was a Senior Vice President at Chandler Corporation, a multi-billion dollar investment fund based in Singapore. In this role, he founded and led the investment team responsible for investing in healthcare businesses in South and Southeast Asia. His responsibilities included leading the on-the-ground incubation and early growth of a regional healthcare chain, as well as serving on the boards of several early-stage healthcare and education businesses throughout the region.

Prior to moving to Singapore in 2008, Dr Patel practiced law at Cravath, Swaine & Moore, and LLP in New York. He received an MD from the Columbia University College of Physicians and Surgeons and a JD from Columbia Law School. Upon graduation, he served as a Clinical Fellow at the Harvard Medical School, and was offered a Fulbright scholarship to study the differences between the Singaporean and US healthcare systems. Dr Patel was a featured speaker at the 2011 Milken Global Conference and is a member of the Society of Kauffman Fellows.

More about Dr Snehal Patel

  • Clinical Fellow at Harvard Medical School
  • Featured speaker at 2011 Milken Global Conference
Board Director / Founder & CEO of CXA Group

Rosaline Chow Koo

Board Director / General Partner at B Capital Group

Gavin Teo

Our Co-Founders

Co-founder / Founder & CEO of Holmusk

Nawal Roy

Nawal is the Founder and CEO of Holmusk – a global digital health platform pioneering in new approaches of looking at long-term illnesses.

Over the years, Nawal has been deeply involved with serving clients across North American, Europe, South East Asia, India, China, Middle East & Africa.

Prior to this, Nawal was the Co-Founder and CEO of HelloPay (Rocket internet venture). Before leading HelloPay, he was a Junior Partner leading client advisory service line in McKinsey & Company. Before Mckinsey, Nawal was the Managing Partner of Shobhit Capital Group, an independent advisory and capital investment firm. Prior to Shobhit Capital, Nawal was a risk management specialist leading ERM initiative at Moody’s Investor Services.

Nawal is one of the founders of PRMIA where he was one of the Directors of Board of PRMIA and Regional Director of the New York Chapter. He has also worked at KPMG, Credit Suisse First Boston and Deutsche Bank.

More about Nawal Roy

  • Co-founder, PRMIA
  • Founder & CEO, HelloPay

Co-founder / CEO of Connected Health

Dr Ronald Ling

Dr Ling is the Founder and Managing Director of Sanus Advisory Asia, an independent advisory firm in Singapore that provides investment and transaction-related services across Asia within the healthcare industry.

A veteran of healthcare investing in Asia with over 20 years experience in consulting, operations and private equity roles, Dr Ling is also Director and Advisor to Connected Health, a Singapore-based remote monitoring and disease management company, and an occasional angel investor. Prior to setting up Sanus Asia, Dr Ling was Managing Director of Pricewaterhouse Cooper’s Healthcare practice and the firm’s Asia Healthcare Leader.

Dr Ling was previously a partner with Symphony Asia (formerly Schroder Capital Partners); a mid-sized private equity firm based in Singapore. At Symphony Dr Ling led healthcare deals and held Board appointments with Parkway Holdings (Asia’s largest private healthcare services company) and Strides Arcolab (a mid-tier listed Indian generic pharmaceutical company), among others

Co-founder / Board Director / Co-Founder & CEO of My-Doc

Dr Snehal Patel

Dr Patel co-founded MyDoc and is also a Managing Director of Saena Partners, a Singapore-based investment company. Previously, he was a Senior Vice President at Chandler Corporation, a multi-billion dollar investment fund based in Singapore. In this role, he founded and led the investment team responsible for investing in healthcare businesses in South and Southeast Asia. His responsibilities included leading the on-the-ground incubation and early growth of a regional healthcare chain, as well as serving on the boards of several early-stage healthcare and education businesses throughout the region.

Prior to moving to Singapore in 2008, Dr Patel practiced law at Cravath, Swaine & Moore, and LLP in New York. He received an MD from the Columbia University College of Physicians and Surgeons and a JD from Columbia Law School. Upon graduation, he served as a Clinical Fellow at the Harvard Medical School, and was offered a Fulbright scholarship to study the differences between the Singaporean and US healthcare systems. Dr Patel was a featured speaker at the 2011 Milken Global Conference and is a member of the Society of Kauffman Fellows.

More about Dr Snehal Patel

  • Clinical Fellow at Harvard Medical School
  • Featured speaker at 2011 Milken Global Conference
Co-founder / Design Director at Orcadesign

Jeremy Sun

Jeremy Sun is the Design Director of Orcadesign Consultants, a forward-thinking innovation and strategy consultancy firm with studios in Singapore and Malaysia. An innovation designer with over 20 years of rich experience, Jeremy has lent his expertise to start-ups, SMEs, global brands and government agencies. He works closely with his clients to reframe challenges, create compelling visions and develop business strategies. Jeremy also advocates a user-centred innovation approach and designs impactful and insightful solutions that resonate with his clients’ target markets.

An avid design educator, Jeremy also conducts collaborative workshops to build innovation capabilities amongst diverse groups and organisations. He is also active in design education and promotion, having lectured in undergraduate programs in design institutions and forums.

Recognised as an industry leader, Jeremy has also been invited to serve as jury for international awards such as iF Award. In addition, Jeremy and his team have received numerous accolades, including the President’s Design Award Singapore, Universal Design Award, IDEA Award and Geneva Innovation Awards.

More about Jeremy Sun

  • Published Empathetic Technology for Ageing – Rethinking Health and Wellness for the Elderly in Singapore: Infocomm Technology Sector
  • Diverse portfolio of clientele including Samsung, Sony, Hewlett-Packard, Rentokil Initial, Welch Allyn, OSIM etc
  • 15 years of experience in design education in Nanyang Polytechnic (NYP), Nanyang Technological University (NTU) and National University of Singapore (NUS)